Introduction
I wanted to find out what it was like to work in scientific academia in the UK and then make the career move into industry, as this is what a lot of our job applicants have done or are currently considering. You may notice from my profile that I, however, have not done this career route myself so I spoke to people who have. I asked scientists CY Partners had helped into various pharmaceutical or Life Science companies for their insight and with their kind permission I am going to share the results here. They have lived it, and these are their views. My cohort spanned from fresh…
AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.Investigating the biological effects of a drug or doing proof of concept assay development, requires a source of the drug. Typically, it is difficult to obtain original pharmaceutical grade biotherapeutic drugs for research use, rather than a clinical application. Consequently, biological compounds almost identical to a reference biologic drug (biosimilars) that have been approved by governmental…
Enables accurate modelling of the human colon and the mucosal barrier
Provides new insights to the relationship between human microbiome and effect on human health
Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ microphysiological systems
Cambridge, UK, 27 July 2021: CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of…
Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development
Appointment supports international growth within ion channel contract research and drug discovery
Cambridge, UK, 26 July 2021: Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced the appointment of Nick Foster as Chief Commercial Officer and Head of Global Business Development, to support the broadening of Metrion’s international customer base and facilitate entry into new territories.…
Reading Scientific Services Ltd (RSSL) has enhanced its Investigative and Quality Control (QC) capabilities with the installation of a new 600 MHz Bruker AVANCE NEO Nuclear Magnetic Resonance (NMR) spectrometer at its UK laboratories. The investment not only increases the scientific consultancy’s capacity to develop tailored analytical solutions, it also paves the way for further investigations into new NMR applications for the Life Science sectors.
The addition of the 600 MHz spectrometer is designed to strengthen and complement RSSL’s existing 400 MHz NMR instrument, which remains in…
Cambridge, United Kingdom – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).
With the In Vitro Diagnostic (IVD) designation, Congenica’s clinical decision support platform can make the transition from research to clinical use and be applied to the clinical diagnosis of patients with rare hereditary genomic disorders. The platform is the only CE marked IVD software for genomic diagnostics…
Increasing numbers of employees are being asked to self-isolate after being exposed to COVID, putting pressure on employers.
Employment lawyer, and Partner, Helen Farr was featured on BBC Radio 5 Live.
Click the link to listen.
SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.
The initial phase of the expansion will see the installation of two 2,000-liter single-use…
20 July 2021: Future Fund: Breakthrough, announced by the Chancellor of the Exchequer at Budget 2021, opens today for applications. This UK-wide programme will deliver £375m of government funding via British Patient Capital, a commercial subsidiary of the British Business Bank.
Due to high research and development costs, breakthrough technology companies typically require more capital than other companies, to fuel the later stages of their growth. Because of their ability to grow rapidly and have a significant economic impact, the growth of these innovative companies is critical to the UK’s…
NHS patients are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million of ringfenced funding, the NHS chief executive has announced today.
The Innovative Medicines Fund (IMF) will build upon the success of the reformed Cancer Drugs Fund (CDF), by supporting patients with any condition, including those with rare and genetic diseases, to get early access to the most clinically promising treatments where further data is needed to support NICE in making final recommendations…